PL3261642T3 - Pochodne chinoliny do zastosowania w leczeniu lub zapobieganiu zakażeniom wirusowym - Google Patents
Pochodne chinoliny do zastosowania w leczeniu lub zapobieganiu zakażeniom wirusowymInfo
- Publication number
- PL3261642T3 PL3261642T3 PL16705929T PL16705929T PL3261642T3 PL 3261642 T3 PL3261642 T3 PL 3261642T3 PL 16705929 T PL16705929 T PL 16705929T PL 16705929 T PL16705929 T PL 16705929T PL 3261642 T3 PL3261642 T3 PL 3261642T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- viral infection
- quinoline derivatives
- quinoline
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305277.4A EP3058940A1 (en) | 2015-02-23 | 2015-02-23 | Quinoline derivatives for use in the treatment or prevention of viral infection |
| EP16705929.4A EP3261642B1 (en) | 2015-02-23 | 2016-02-19 | Quinoline derivatives for use in the treatment or prevention of viral infection |
| PCT/EP2016/053535 WO2016135055A1 (en) | 2015-02-23 | 2016-02-19 | Quinoline derivatives for use in the treatment or prevention of viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3261642T3 true PL3261642T3 (pl) | 2021-11-15 |
Family
ID=52629499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16705929T PL3261642T3 (pl) | 2015-02-23 | 2016-02-19 | Pochodne chinoliny do zastosowania w leczeniu lub zapobieganiu zakażeniom wirusowym |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10806729B2 (pl) |
| EP (2) | EP3058940A1 (pl) |
| JP (1) | JP6826988B2 (pl) |
| KR (1) | KR102650958B1 (pl) |
| CN (1) | CN107635559A (pl) |
| AU (1) | AU2016223599B2 (pl) |
| BR (1) | BR112017017505A2 (pl) |
| CA (1) | CA2975777C (pl) |
| DK (1) | DK3261642T3 (pl) |
| ES (1) | ES2882542T3 (pl) |
| HR (1) | HRP20211172T1 (pl) |
| HU (1) | HUE055592T2 (pl) |
| LT (1) | LT3261642T (pl) |
| MX (2) | MX382760B (pl) |
| PL (1) | PL3261642T3 (pl) |
| PT (1) | PT3261642T (pl) |
| RS (1) | RS62173B1 (pl) |
| RU (1) | RU2723016C2 (pl) |
| SI (1) | SI3261642T1 (pl) |
| WO (1) | WO2016135055A1 (pl) |
| ZA (1) | ZA201705634B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3669873A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| JP7833398B2 (ja) * | 2019-11-26 | 2026-03-19 | バイオトロン リミティッド | Ｈｉｖ－１感染を治療する方法 |
| KR102399037B1 (ko) * | 2020-01-06 | 2022-05-17 | 성균관대학교산학협력단 | 아민화된 아진의 신규한 제조방법 |
| EP3881844A1 (en) * | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| BR112022018793A2 (pt) * | 2020-03-20 | 2022-11-29 | Abivax | Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae |
| EP3884946A1 (en) * | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| CN114931580B (zh) * | 2022-05-26 | 2024-04-19 | 军事科学院军事医学研究院军事兽医研究所 | 依曲韦林在抗狂犬病病毒中的应用和抗狂犬病病毒药物的筛选方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354853A (en) * | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| TR201910781T4 (tr) * | 2009-06-12 | 2019-08-21 | Abivax | Kanser tedavisi için yararlı bileşikler. |
| EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| US9827237B2 (en) * | 2013-07-05 | 2017-11-28 | Abivax | Compounds useful for treating diseases caused by retroviruses |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
-
2015
- 2015-02-23 EP EP15305277.4A patent/EP3058940A1/en not_active Withdrawn
-
2016
- 2016-02-19 RU RU2017128644A patent/RU2723016C2/ru active
- 2016-02-19 EP EP16705929.4A patent/EP3261642B1/en active Active
- 2016-02-19 DK DK16705929.4T patent/DK3261642T3/da active
- 2016-02-19 LT LTEP16705929.4T patent/LT3261642T/lt unknown
- 2016-02-19 US US15/552,921 patent/US10806729B2/en active Active
- 2016-02-19 SI SI201631277T patent/SI3261642T1/sl unknown
- 2016-02-19 AU AU2016223599A patent/AU2016223599B2/en not_active Ceased
- 2016-02-19 ES ES16705929T patent/ES2882542T3/es active Active
- 2016-02-19 PT PT167059294T patent/PT3261642T/pt unknown
- 2016-02-19 HU HUE16705929A patent/HUE055592T2/hu unknown
- 2016-02-19 WO PCT/EP2016/053535 patent/WO2016135055A1/en not_active Ceased
- 2016-02-19 MX MX2017010623A patent/MX382760B/es unknown
- 2016-02-19 CN CN201680011581.6A patent/CN107635559A/zh active Pending
- 2016-02-19 CA CA2975777A patent/CA2975777C/en active Active
- 2016-02-19 RS RS20210964A patent/RS62173B1/sr unknown
- 2016-02-19 JP JP2017544314A patent/JP6826988B2/ja active Active
- 2016-02-19 PL PL16705929T patent/PL3261642T3/pl unknown
- 2016-02-19 HR HRP20211172TT patent/HRP20211172T1/hr unknown
- 2016-02-19 BR BR112017017505-3A patent/BR112017017505A2/pt not_active Application Discontinuation
- 2016-02-19 KR KR1020177026021A patent/KR102650958B1/ko active Active
-
2017
- 2017-08-17 MX MX2021006636A patent/MX2021006636A/es unknown
- 2017-08-18 ZA ZA2017/05634A patent/ZA201705634B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2723016C2 (ru) | 2020-06-08 |
| KR20170125850A (ko) | 2017-11-15 |
| RU2017128644A (ru) | 2019-03-25 |
| CA2975777C (en) | 2022-12-13 |
| LT3261642T (lt) | 2021-07-26 |
| MX382760B (es) | 2025-03-13 |
| RS62173B1 (sr) | 2021-08-31 |
| AU2016223599A1 (en) | 2017-08-31 |
| KR102650958B1 (ko) | 2024-03-22 |
| ES2882542T3 (es) | 2021-12-02 |
| EP3261642A1 (en) | 2018-01-03 |
| EP3261642B1 (en) | 2021-05-19 |
| HRP20211172T1 (hr) | 2021-12-24 |
| MX2021006636A (es) | 2021-07-07 |
| ZA201705634B (en) | 2018-12-19 |
| AU2016223599B2 (en) | 2021-03-11 |
| WO2016135055A1 (en) | 2016-09-01 |
| HUE055592T2 (hu) | 2021-12-28 |
| DK3261642T3 (da) | 2021-08-09 |
| US10806729B2 (en) | 2020-10-20 |
| PT3261642T (pt) | 2021-08-02 |
| US20180028522A1 (en) | 2018-02-01 |
| BR112017017505A2 (pt) | 2018-04-17 |
| CN107635559A (zh) | 2018-01-26 |
| EP3058940A1 (en) | 2016-08-24 |
| SI3261642T1 (sl) | 2021-10-29 |
| JP6826988B2 (ja) | 2021-02-10 |
| JP2018505909A (ja) | 2018-03-01 |
| CA2975777A1 (en) | 2016-09-01 |
| RU2017128644A3 (pl) | 2019-04-15 |
| MX2017010623A (es) | 2018-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272820B (en) | The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b | |
| IL263972A (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| IL246449B (en) | Conjugated 6-heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis b virus infection | |
| ZA201705634B (en) | Quinoline derivatives for use in the treatment or prevention of viral infection | |
| ZA201705633B (en) | A new quinoline derivative for use in the treatment and prevention of viral infections | |
| IL245436A0 (en) | New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection | |
| IL280769A (en) | New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection | |
| IL263368A (en) | Prevention and treatment of viral infections | |
| PL3183003T3 (pl) | SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA | |
| EP3280422A4 (en) | Compositions and methods for the treatment of hbv infection | |
| EP2978449A4 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| IL247938A0 (en) | Onconas for use in the treatment or prevention of viral infections | |
| GB201615035D0 (en) | Treatment and prevention of viral infection | |
| PL3095866T3 (pl) | Środek do profilaktyki i terapii infekcji wirusowych | |
| ZA201604784B (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| AU2014900488A0 (en) | Agents and methods for inhibiting virus infection |